Boston Scientific Brain Pacemaker’s 16-Contact Directional Electrode Debuts, Further Advances in Precise Neuromodulation

Shanghai, November 6, 2026 - During the 9th China International Import Expo, Boston Scientific officially released a new generation of Vercise Cartesia X and HX16 contact implantable deep brain neurostimulation electrodes* at the CIIE booth. As brand new members of the Vercise Genus deep brain stimulation system, Vercise Cartesia X and HX are the world's first and currently only 16-contact directional electrodes, which will provide more precise, more diverse and more personalized new treatment options for neurological diseases such as Parkinson's disease.

Parkinson's disease is a common neurological degenerative disease in middle-aged and elderly people. Relevant epidemiological studies show that the number of Parkinson's disease patients in China has exceeded 5 million. Although drug treatment can control some symptoms, the effectiveness of the drugs gradually becomes less effective as the disease progresses, and side effects may occur. Brain pacemaker, also known as deep brain stimulation (DBS) therapy, has become a safe and effective treatment method because of its minimally invasive, reversible, and adjustable advantages. This therapy can stimulate target nerve nuclei by implanting electrodes in the brain, regulate related neural circuits, improve motor symptoms and reduce drug use.

Due to differences in the location, shape and surrounding tissue structure of nerve nuclei in the brain of different patients, DBS treatment not only requires precise positioning of the stimulation target, but also requires flexible adjustment of stimulation parameters according to the patient's individual condition. How to achieve more precise and flexible stimulation control has become an important direction for the sustainable development of DBS technology.

The new generation of Vercise Cartesia 16-contact implantable deep brain nerve stimulation electrode released at the CIIE is an important component of Boston Scientific's Vercise Genus deep brain nerve stimulation system. Based on the original 8-contact design, it has been further upgraded to provide doctors with a precise neuromodulation tool with "more targets and more choices" through a richer directional contact layout, wider stimulation coverage and refined current control.

Vercise Cartesia X and HX16 contact implantable deep brain neurostimulation electrodes

·Wide-area coverage, precise point selection: The 16-contact design further expands the directional stimulation coverage, and the close contact spacing provides doctors with more space to select stimulation areas based on different patients' brain anatomy and target locations.

·Independent current control and flexible shaping: Directional electrodes combined with Boston Scientific Multiple Independent Current Control (MICC) technology can independently distribute current to different contacts, flexibly adjust stimulation direction and intensity, and achieve more flexible stimulation field shaping.

·Multiple choices, individual adaptation: Richer contact point configurations and stimulation parameter choices allow doctors to flexibly adjust the program control plan based on the patient's brain anatomy, symptom performance and treatment response, providing more support for individualized treatment and long-term symptom management.

The debut of the 16-contact directional electrode at the Expo further enriches the product portfolio of Boston Scientific's Vercise Genus deep brain neurostimulation system, and also reflects Boston Scientific's forward-looking layout in the field of neuromodulation. In the future, Boston Scientific will continue to deepen exchanges and cooperation with Chinese clinical experts, promote the clinical application of innovative precision medicine technology, help develop the diagnosis and treatment of Parkinson's disease, and improve the quality of life of patients.

*This product is not yet available in mainland China